FDA Approves Infilbray As First Neurological Gaucher Treatment
The Food and Drug Administration approved Sanofi's oral venglustat, branded Infilbray, on Wednesday for the neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kilograms, the first treatment authorized for those symptoms.
Edited and fact-checked by Stephen Sprague
Infilbray enters type 3 Gaucher care as a daily pill beside the existing infusions, and its published effect size is still owed to families.
The Food and Drug Administration approved venglustat, branded Infilbray, on Wednesday, November 18, for the neurological symptoms of type 3 Gaucher disease. The approval covers adults and children weighing at least 15 kilograms, about 33 pounds. Type 3 Gaucher disease is a rare inherited disorder, and in people who carry it, fatty substances called glucosphingolipids accumulate in the body and the brain because an enzyme pathway fails to break them down.
Venglustat is taken by mouth once a day, and it inhibits glucosylceramide synthase, the enzyme that builds the substances the disease cannot clear. The drug crosses the blood-brain barrier, and that single property explains the approval's place in the treatment landscape. Enzyme replacement therapy has controlled the body's side of Gaucher disease for years on an every-two-week infusion schedule, and those infusions do not reach the brain, so the neurological symptoms families watch in muscle control, coordination and thinking had no authorized treatment before Wednesday.
The evidence comes from a randomized, double-blind, multicenter trial that enrolled 43 patients aged 12 years and older, each with systemic disease already stabilized on enzyme replacement therapy. Over 52 weeks, patients taking Infilbray once daily improved on a combined measure of muscle control, coordination and cognitive function when compared with patients who continued on enzyme replacement therapy alone. The trial design means the drug was tested as an addition to existing care in a stable population, and the results should be read on those terms.
Two limits sit inside the approval record itself, and families weighing the drug deserve both in plain view. The FDA announcement provided no numerical estimates of the treatment effect, so the public record establishes the direction of the benefit without stating its size, and 43 patients is a small evidence base even by rare-disease standards. The most commonly reported side effects in the program were gastrointestinal problems and effects on mood, which treating physicians will have to weigh against a benefit whose magnitude has not been published.
The agency granted venglustat Orphan Drug designation and Priority Review ahead of the decision, and the approval went to Genzyme Corporation, the Sanofi unit that developed the drug. What changes on the ground is concrete. A child or adult with type 3 Gaucher disease now has a daily pill directed at the neurological disease itself, taken alongside the infusions that manage the rest of the condition, and the first authorized option for the symptoms that define how the disease progresses.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.